📣 VC round data is live. Check it out!
- Public Comps
- Tristel
Tristel Valuation Multiples
Discover Tristel's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Stille, Prim, Standard Glass Lining, Bastide Le Confort Médical and more.
Tristel Overview
About Tristel
Tristel PLC’s business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
Founded
2003
HQ

Employees
265
Website
Sectors
Financials (LTM)
EV
$235M
Valuation Multiples
Start free trialTristel Financials
Tristel reported last 12-month revenue of $68M and EBITDA of $19M.
In the same LTM period, Tristel generated $56M in gross profit, $19M in EBITDA, and $11M in net income.
Revenue (LTM)
Tristel P&L
In the most recent fiscal year, Tristel reported revenue of $63M and EBITDA of $17M.
Tristel is profitable as of last fiscal year, with gross margin of 81%, EBITDA margin of 27%, and net margin of 17%.
Financial data powered by Morningstar, Inc.
Tristel Stock Performance
Tristel has current market cap of $245M, and enterprise value of $235M.
Market Cap Evolution
Tristel's stock price is $5.11.
Tristel share price decreased by 0.6% in the last 30 days, and by 6.6% in the last year.
Tristel has an EPS (earnings per share) of $0.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $235M | $245M | 0.1% | -0.6% | 4.7% | -6.6% | $0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTristel Valuation Multiples
Tristel trades at 3.4x EV/Revenue multiple, and 12.5x EV/EBITDA.
EV / Revenue (LTM)
Tristel Financial Valuation Multiples
As of June 4, 2026, Tristel has market cap of $245M and EV of $235M.
Tristel has a P/E ratio of 22.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tristel Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Tristel Margins & Growth Rates
Tristel grew revenue by 10% and EBITDA by 11% in the last fiscal year.
In the most recent fiscal year, Tristel reported gross margin of 81%, EBITDA margin of 27%, and net margin of 17%.
Tristel Margins
Tristel Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Tristel Operational KPIs
Tristel's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Tristel's Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tristel's Rule of X is 53% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Tristel Competitors
Tristel competitors include Stille, Prim, Standard Glass Lining, Bastide Le Confort Médical, Embecta, KORU Medical Systems, Paragon Care, Quipt Home Medical, Medika and Mercator Medical.
Most Tristel public comparables operate across Medical Supplies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.0x | 3.7x | 20.1x | 17.7x | |||
| 0.9x | - | 6.3x | - | |||
| - | - | - | - | |||
| 0.9x | 0.9x | 4.5x | 4.5x | |||
| 1.3x | 1.3x | 3.3x | 4.0x | |||
| 4.4x | 4.1x | 277.4x | 175.2x | |||
| 0.2x | 0.2x | 7.2x | 6.3x | |||
| - | 1.1x | - | - | |||
This data is available for Pro users. Sign up to see all Tristel competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Tristel
Tristel has acquired 2 companies to date.
Last acquisition by Tristel was on November 19th 2018. Tristel acquired Ecomed Group for $5M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Tristel
| Description | - | AshMed is a Melbourne-based supplier of surgical and medical equipment across Australia and New Zealand. The company distributes products such as endoscopic devices, orthopedic implants, and sterilization solutions, supported by a sales team with collective expertise exceeding 50 years in specialized fields. |
| HQ Country | ||
| HQ City | - | Melbourne |
| Deal Date | 19 Nov 2018 | 21 Jul 2016 |
| Valuation | $5M | $1M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Tristel acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by Tristel
Tristel has invested in 1 company to date.
Latest investment by Tristel was on August 12th 2020. Tristel invested in MobileODT in their $4M Series C round (EV/Revenue multiple available to Pro users).
Latest Investments by Tristel
| Description | MobileODT is a medtech company developing connected visual diagnostics tools, including the FDA-cleared EVA System, a portable colposcope for cervical cancer screening. The device streams high-resolution images to smartphones for AI-assisted analysis, deployed in 29 countries from rural clinics in Africa to hospitals like MD Anderson and Mount Sinai. Tel Aviv-headquartered MobileODT expands into ENT and dermatology applications, prioritizing low-resource settings. | MobileODT is a medtech company developing connected visual diagnostics tools, including the FDA-cleared EVA System, a portable colposcope for cervical cancer screening. The device streams high-resolution images to smartphones for AI-assisted analysis, deployed in 29 countries from rural clinics in Africa to hospitals like MD Anderson and Mount Sinai. Tel Aviv-headquartered MobileODT expands into ENT and dermatology applications, prioritizing low-resource settings. |
| HQ Country | ||
| HQ City | Tel Aviv | Tel Aviv |
| Deal Date | 12 Aug 2020 | 5 Jul 2017 |
| Round | Series C | Series B |
| Raised | $4M | $7M |
| Investors | Laerdal Million Lives Fund; OrbiMed; Tara Health Foundation; Tristel | OrbiMed; Tristel |
| Valuation | undisclosed | $23M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Tristel investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tristel
| When was Tristel founded? | Tristel was founded in 2003. |
| Where is Tristel headquartered? | Tristel is headquartered in United Kingdom. |
| How many employees does Tristel have? | As of today, Tristel has over 265 employees. |
| Who is the CEO of Tristel? | Tristel's CEO is Matthew Giovanni Sassone. |
| Is Tristel publicly listed? | Yes, Tristel is a public company listed on London Stock Exchange. |
| What is the stock symbol of Tristel? | Tristel trades under TSTL ticker. |
| When did Tristel go public? | Tristel went public in 2005. |
| Who are competitors of Tristel? | Tristel main competitors include Stille, Prim, Standard Glass Lining, Bastide Le Confort Médical, Embecta, KORU Medical Systems, Paragon Care, Quipt Home Medical, Medika, Mercator Medical. |
| What is the current market cap of Tristel? | Tristel's current market cap is $245M. |
| What is the current revenue of Tristel? | Tristel's last 12 months revenue is $68M. |
| What is the current revenue growth of Tristel? | Tristel revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Tristel? | Current revenue multiple of Tristel is 3.4x. |
| What is the current EBITDA of Tristel? | Tristel's last 12 months EBITDA is $19M. |
| What is Tristel's EBITDA margin? | Tristel's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Tristel? | Current EBITDA multiple of Tristel is 12.5x. |
| What is the current FCF of Tristel? | Tristel's last 12 months FCF is $12M. |
| What is Tristel's FCF margin? | Tristel's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Tristel? | Current FCF multiple of Tristel is 19.6x. |
| How many companies Tristel has acquired to date? | As of June 2026, Tristel has acquired 2 companies. |
| What was the largest acquisition by Tristel? | $5M acquisition of Ecomed Group on 19th November 2018 was the largest M&A Tristel has done to date. |
| What companies Tristel acquired? | Tristel acquired Ecomed Group and AshMed. |
| In how many companies Tristel has invested to date? | As of June 2026, Tristel has invested in 1 company. |
| What was the last Tristel investment? | On 12th August 2020 Tristel invested in MobileODT, participating in a $4M Series C round, alongside Laerdal Million Lives Fund, OrbiMed, and Tara Health Foundation. |
| In what companies Tristel invested in? | Tristel invested in MobileODT. |
See public comps similar to Tristel
Lists including Tristel
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


